Tuberculosis in pediatric patients treated with anti-TNFα drugs: A cohort study

Pediatric Rheumatology

Volumn 13, Issue 1, 2015, Pages

  Calzada Hernández, Joan ^a   Anton López, Jordi ^a   Bou Torrent, Rosa ^a   Iglesias Jiménez, Estíbaliz ^a   Ricart Campos, Sílvia ^a   Martín de Carpi, Javier ^a   Muñoz de la Nava, Carmen García de Vicuña ^a   Torrente Segarra, Vicenç ^a   Sánchez Manubens, Judith ^a   Giménez Roca, Clara ^a   Rozas Quesada, Librada ^a   Juncosa Morros, Maria Teresa ^a   Fortuny, Clàudia ^a   Noguera Julian, Antoni ^a  

^a UNIVERSITY OF BARCELONA   (Spain)

Author keywords

Anti tumor necrosis factor alpha drugs; Inflammatory bowel disease; Interferon gamma release assays; Juvenile idiopathic arthritis; Tuberculosis

Indexed keywords

ADALIMUMAB; ETANERCEPT; INFLIXIMAB; TUMOR NECROSIS FACTOR;

ARTICLE; CHEMOPROPHYLAXIS; CHILD; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE DURATION; EYE DISEASE; FEMALE; FOLLOW UP; HUMAN; INFLAMMATORY BOWEL DISEASE; JUVENILE RHEUMATOID ARTHRITIS; LATENT TUBERCULOSIS; MAJOR CLINICAL STUDY; MALE; MASS SCREENING; OBSERVATIONAL STUDY; PHYSICAL EXAMINATION; PREVALENCE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RHEUMATIC DISEASE; SPAIN; TERTIARY CARE CENTER; TUBERCULIN TEST; ADOLESCENT; ANTAGONISTS AND INHIBITORS; INTERFERON GAMMA RELEASE ASSAY; PRESCHOOL CHILD;

ADOLESCENT; CHILD; CHILD, PRESCHOOL; FEMALE; HUMANS; INTERFERON-GAMMA RELEASE TESTS; LATENT TUBERCULOSIS; MALE; PREVALENCE; RETROSPECTIVE STUDIES; TUBERCULIN TEST; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84949191292     PISSN: None     EISSN: 15460096     Source Type: Journal    
DOI: 10.1186/s12969-015-0054-4     Document Type: Article

References (23)

1. Tubach F, Salmon D, Ravaud P, Allanore Y, Goupille P, Bréban M, et al. Risk of tuberculosis is higher with anti-tumor necrosis factor monoclonal antibody therapy than with soluble tumor necrosis factor receptor therapy: The three-year prospective French Research Axed on Tolerance of Biotherapies registry. Arthritis Rheum. 2009;60:1884-94.
2. Ormerod LP, Milburn HJ, Gillespie S, Ledingham J, Rampton D. British Thoracic Society Standards of Care Committee. BTS recommendations for assessing risk and for managing mycobacterium tuberculosis infection and disease in patients due to start anti-TNF-alpha treatment. Thorax. 2005;60:800-5.
3. Mohan AK, Coté TR, Block JA, Manadan AM, Siegel JN, Braun MM. Tuberculosis following the use of etanercept, a tumor necrosis factor inhibitor. Clin Infect Dis. 2004;39:295-9.
4. Woerner A, Ritz N. Infections in children treated with biological agents. Pediatr Infect Dis J. 2013;32:284-8.
5. Moreno-Pérez D, Andrés Martín A, Altet Gómez N, Baquero-Artigao F, Escribano Montaner A, Gómez-Pastrana Durán D, et al. Diagnosis of tuberculosis in pediatrics. Consensus document of the Spanish Society of Pediatric Infectology (SEIP) and the Spanish Society of Pediatric Pneumology (SENP). An Pediatr (Barc). 2010. doi: 10.1016/j.anpedi.2009.12.017.
6. Toussi SS, Pan N, Walters HM, Walsh TJ. Infections in children and adolescents with juvenile idiopathic arthritis and inflammatory bowel disease treated with tumor necrosis factor-α inhibitors: systematic review of the literature. Clin Infect Dis. 2013;57:1318-30.
7. Ruperto N, Lovell DJ, Cuttica R, Wilkinson N, Woo P, Espada G, et al. A randomized, placebo-controlled trial of infliximab plus methotrexate for the treatment of polyarticular-course juvenile rheumatoid arthritis. Arthritis Rheum. 2007;56:3096-106.
8. Armbrust W, Kamphuis SS, Wolfs TW, Fiselier TJ, Nikkels PG, Kuis W, et al. Tuberculosis in a nine-year-old girl treated with infliximab for systemic juvenile idiopathic arthritis. Rheumatology (Oxford). 2004;43:527-9.
9. Myers A, Clark J, Foster H. Tuberculosis and treatment with infliximab. N Engl J Med. 2002;346:623-6.
10. Hess S, Hospach T, Nossal R, Dannecker G, Magdorf K, Uhlemann F. Life-threatening disseminated tuberculosis as a complication of TNF-α blockade in an adolescent. Eur J Pediatr. 2011;170:1337-42.
11. Kharbanda P, Dagaonkar R, Balakrishnan C, Udwadia ZF. Tumor necrosis factor-alpha blocker induced tuberculosis. J Rheumatol. 2010;37:1542.
12. Cruz AT, Karam LB, Orth RC, Starke JR. Disseminated tuberculosis in two children with inflammatory bowel disease receiving infliximab. Pediatr Infect Dis J. 2014;33:779-81.
13. Jordan N, Waghmare A, Abi-Ghanem AS, Moon A, Salvatore CM. Systemic mycobacterium avium complex infection during antitumor necrosis factor-a therapy in pediatric Crohn disease. J Pediatr Gastroenterol Nutr. 2012;54:294-6.
14. Cheent K, Nolan J, Shariq S, Kiho L, Pal A, Arnold J. Case report: Fatal case of disseminated BCG infection in an infant born to a mother taking infliximab for Crohn's disease. J Crohns Colitis. 2010;4:603-5.
15. Sacristán AM, Casares I, Lage MJ. Prevalencia de infección tuberculosa en adolescentes de 11 a 14 años en Palencia. Rev Pediatr Aten Primaria. 2004;6:9-17.
16. Ayaz NA, Demirkaya E, Bilginer Y, Ozçelik U, Cobanoğlu N, Kiper N, et al. Preventing tuberculosis in children receiving anti-TNFα treatment. Clin Rheumatol. 2010;29:389-92.
17. Cagatay T, Aydin M, Sunmez S, Cagatay P, Gulbaran Z, Gul A, et al. Follow-up results of 702 patients receiving tumor necrosis factor-α antagonists and evaluation of risk of tuberculosis. Rheumatol Int. 2010;30:1459-63.
18. Kilic O, Kasapcopur O, Camcioglu Y, Cokugras H, Arisoy N, Akcakaya N. Is it safe to use anti-TNF-α agents for tuberculosis in children suffering with chronic rheumatic disease? Rheumatol Int. 2012;32:2675-9.
19. Maritsi D, Al-Obadi M, Brogan PA, Eleftheriou D, Dixon GL. The performance of Quantiferon TB Gold in-Tube as a screening tool in paediatric rheumatology prior to initiation of infliximab: a single centre's experience. ISRN Rheumatol. 2011. doi: 10.5402/2011/505171.
20. Mariette X, Baron G, Tubach F, Lioté F, Combe B, Miceli-Richard C, et al. Influence of replacing tuberculin skin test with ex vivo interferon γ release assays on decision to administer prophylactic antituberculosis antibiotics before anti-TNFα therapy. Ann Rheum Dis. 2012;71:1783-90.
21. Kleinert S, Tony HP, Krueger K, Detert J, Mielke F, Rockwitz K, et al. Screening for latent tuberculosis infection: performance of tuberculin skin test and interferon-γ release assays under real-life conditions. Ann Rheum Dis. 2012;71:1791-5.
22. Winthrop KL, Weinblatt ME, Daley CL. You can't always get what you want, but if you try sometimes (with two tests--TST and IGRA--for tuberculosis) you get what you need. Ann Rheum Dis. 2012;71:1757-60.
23. Hradsky O, Ohem J, Zarubova K, Mitrova K, Durilova M, Kotalova R, et al. Disease activity is an important factor for indeterminate interferon-γ release assay results in children with inflammatory bowel disease. J Pediatr Gastroenterol Nutr. 2014;58:320-4.